Layer3.news — Martin Auster

RAYMOND JAMES INCREASES PT ON DYNE THERAPEUTICS STOCK FROM $31 TO $35, MAINTAINS BUY RATING

https://s.yimg.com/ny/api/res/1.2/jDYzkoXB7yikvQEqZpA0Kw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/d83040bc6b2781bf0defce9c131f5a82

✍️ Dyne Therapeutics, Inc. (NASDAQ:DYN) is a clinical-stage neuromuscular disease company that focuses on discovering and developing therapeutics for neuromuscular diseases.

👉 Dyne Therapeutics, Inc. (NASDAQ:DYN) has received a price target increase from Raymond James 👉 Analyst maintains a Buy rating 👉 Company's investigational exon-skipping therapy for Duchenne Muscular Dystrophy (DMD) has received Breakthrough Therapy Designation from the FDA 👉 Expected to file a Biologics License Application (BLA) in early 2026 👉 Analyst sees potential in the upcoming investigational therapy for DMD

-- #MartinAuster #DougKerr #business

Loading quoted post…

nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqah7lmcxux5x3mc60aqhfv8f85pe926wzuwtscvh9h2p46s7wxkjswm7s4j

Martin Auster Doug Kerr business mainstream:perspective

9/11/2025

npub1vap2usg…grwc3n

RAYMOND JAMES PREDICTS UP TO ~760% SURGE FOR THESE 2 ‘STRONG BUY’ STOCKS

https://media.zenfs.com/en/tipranks_452/145eeadd8e0dde5c379864dad25e4a1a

✍️ President Trump's recent trade moves have stirred up uncertainty, but Raymond James CIO Larry Adam remains optimistic about the long-term prospects of the US equities market. Two stocks, Achieve Life Sciences (ACHV) and Avidity Biosciences (RNA), are highlighted as having potential for substantial growth in the coming year.

👉 President Trump's recent trade moves have stirred up uncertainty in the market 👉 Raymond James CIO Larry Adam remains optimistic about the long-term prospects of the US equities market 👉 Achieve Life Sciences (ACHV) is a biopharmaceutical company developing treatments for nicotine dependence 👉 Avidity Biosciences (RNA) is a clinical-stage biotech firm developing RNA therapeutics 👉 Both companies have strong clinical profiles and are advancing towards key clinical and regulatory milestones